Sermorelin
Sermorelin Acetate (GHRH 1-29)
A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates natural GH production. FDA-approved for diagnosing GH deficiency and treating growth failure in children.
Typical Cost
$200-400/month
Status
Research
Peptide Profile
Sermorelin
Mechanism of Action
Stimulates pituitary to release endogenous growth hormone. Preserves natural GH pulsatility and feedback mechanisms. Shorter half-life than CJC-1295.
Common Dosages
subcutaneous
0.2-0.3mg
Daily at bedtime · 3-6 months
Benefits
FDA-approved
Natural GH pulsatility
No GH shutdown
Diagnostic utility
Well-studied
Side Effects
Injection site reactions
Flushing
Headache
Nausea
Short half-life
Key Research
Sermorelin GH stimulation
FDA approval based on efficacy in GH deficiency
Regulatory Status
FDA-approved (Geref) for GH deficiency diagnosis and pediatric growth failure. Also used off-label in anti-aging.
Contraindications
- ⚠Active cancer
- ⚠Pregnancy/breastfeeding
- ⚠Closed epiphyses (children)
GLP-1 users seeking GH support may discuss sermorelin with healthcare provider alongside SeraVia formulations.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.